Danone reinforces European medical nutrition manufacturing footprint with €50 million line expansion in Poland

Danone today announces a €50 million line expansion of its Opole, Poland, production facility, to expand its medical nutrition capabilities to serve patients across the world, as it targets further growth in the adult medical nutrition market.

The expansion comes as macro trends point to a growing demand for the category as populations continue to age and the rate of chronic diseases increases. Many people will require medical nutrition at some stage of their lives, with diseases such as cancer and strokes resulting in malnutrition of patients. Although medical nutrition is proven to support patient outcomes, only one in three patients who could benefit from it currently receive it – showing that there is a growing need for medical nutrition solutions.

Specialized nutrition (which includes medical nutrition) accounts for 30% of Danone’s total revenues, with a growth of +10% like-for-like in 2022. This investment marks further progress against the Renew Danone strategy to drive growth within its categories, and notably in its medical nutrition activities where Danone aims at serving a growing number of patients.

Danone is already the market leader across Europe in adult medical nutrition. The Opole investment will allow Danone to expand its highly specialized production capabilities through a new medical nutrition production line which will serve patients who are dependent on feeding tubes as they cannot swallow or drink normally. Opole will be Danone’s second European plant to produce Danone’s enteral nutrition range Nutrison.